LIQUIDIA CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
LIQUIDIA CORPORATION (LQDA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $9.84 per share for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-05
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $9.84, a 105.00% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $4.80, a 9.84% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $4.37, a 109.09% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $2.09, a 12.18% decline year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $9.84, a 93.32% increase from fiscal 2023.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $5.09, a 29.19% increase from fiscal 2022.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $3.94, a 76.68% increase from fiscal 2021.
- LIQUIDIA CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $2.23, a 19.78% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-09-30 | $9.84 10-Q · filed 2025-11-03 | |||
| 2025-06-30 | $9.84 10-Q · filed 2025-08-12 | |||
| 2024-12-31 | $9.84 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $9.84 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $9.84 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $9.84 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $5.09 10-K · filed 2026-03-05 | |||
| 2023-09-30 | $5.09 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $5.09 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $4.80 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $3.94 10-K · filed 2024-03-13 | |||
| 2022-09-30 | $4.11 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $4.19 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $4.37 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $2.23 10-K · filed 2023-03-20 | |||
| 2021-09-30 | $2.02 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $2.08 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $2.09 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $2.78 10-K · filed 2022-03-17 | |||
| 2020-09-30 | $4.16 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $3.65 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | $2.38 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $8.00 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |